Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial
Abstract Background: Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some countries. Methods: In a multicentre open-label, randomised, controlled, adaptive platform trial, low-risk adult patients with early symptomatic COVID-19 were randomised to one of ten treatment arms including high dose oral favipiravir (3.6g on day 0 followed by 1.6g daily to complete 7 days treatment) or no study drug. The primary outcome assessed in a modified intention-to-treat population (mITT) was the rate of viral clearance (derived under a linear mixed-effects model from the daily log10 viral densities in standardised duplicate oropharyngeal swab eluates taken daily over 8 days [18 swabs per patient]). The safety population included all patients who received at least one dose of the allocated intervention. This ongoing adaptive platform trial is registered at ClinicalTrials.gov (NCT05041907). Results: In the final analysis, the mITT population contained data from 114 patients randomised to favipiravir and 126 patients randomised concurrently to no study drug. Under the linear mixed-effects model fitted to all oropharyngeal viral density estimates in the first 8 days from randomisation (4,318 swabs), there was no difference in the rate of viral clearance between patients administered favipiravir and patients receiving no study drug -1% (95% CI: -14 to 14% change). High dose favipiravir was well tolerated. Interpretation: Favipiravir does not accelerate viral clearance in early symptomatic COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ResearchSquare.com - (2024) vom: 22. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2675703/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA039180778 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA039180778 | ||
| 003 | DE-627 | ||
| 005 | 20240123130440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230406s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2675703/v1 |2 doi | |
| 035 | |a (DE-627)XRA039180778 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2675703/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luvira, Viravarn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some countries. Methods: In a multicentre open-label, randomised, controlled, adaptive platform trial, low-risk adult patients with early symptomatic COVID-19 were randomised to one of ten treatment arms including high dose oral favipiravir (3.6g on day 0 followed by 1.6g daily to complete 7 days treatment) or no study drug. The primary outcome assessed in a modified intention-to-treat population (mITT) was the rate of viral clearance (derived under a linear mixed-effects model from the daily log10 viral densities in standardised duplicate oropharyngeal swab eluates taken daily over 8 days [18 swabs per patient]). The safety population included all patients who received at least one dose of the allocated intervention. This ongoing adaptive platform trial is registered at ClinicalTrials.gov (NCT05041907). Results: In the final analysis, the mITT population contained data from 114 patients randomised to favipiravir and 126 patients randomised concurrently to no study drug. Under the linear mixed-effects model fitted to all oropharyngeal viral density estimates in the first 8 days from randomisation (4,318 swabs), there was no difference in the rate of viral clearance between patients administered favipiravir and patients receiving no study drug -1% (95% CI: -14 to 14% change). High dose favipiravir was well tolerated. Interpretation: Favipiravir does not accelerate viral clearance in early symptomatic COVID-19. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Schilling, William HK |4 aut | |
| 700 | 1 | |a Jittamala, Podjanee |4 aut | |
| 700 | 1 | |a Watson, James A |4 aut | |
| 700 | 1 | |a Boyd, Simon |4 aut | |
| 700 | 1 | |a Siripoon, Tanaya |4 aut | |
| 700 | 1 | |a Ngamprasertchai, Thundon |4 aut | |
| 700 | 1 | |a Almeida, Pedro J |4 aut | |
| 700 | 1 | |a Ekkapongpisit, Maneerat |4 aut | |
| 700 | 1 | |a Cruz, Cintia |4 aut | |
| 700 | 1 | |a Callery, James J |4 aut | |
| 700 | 1 | |a Singh, Shivani |4 aut | |
| 700 | 1 | |a Tuntipaiboontana, Runch |4 aut | |
| 700 | 1 | |a Kruabkontho, Varaporn |4 aut | |
| 700 | 1 | |a Ngernseng, Thatsanun |4 aut | |
| 700 | 1 | |a Tubprasert, Jaruwan |4 aut | |
| 700 | 1 | |a Abdad, Mohammad Yazid |4 aut | |
| 700 | 1 | |a Keayarsa, Srisuda |4 aut | |
| 700 | 1 | |a Madmanee, Wanassanan |4 aut | |
| 700 | 1 | |a Aguiar, Renato S |4 aut | |
| 700 | 1 | |a Santos, Franciele M |4 aut | |
| 700 | 1 | |a Hanboonkunupakarn, Pongtorn |4 aut | |
| 700 | 1 | |a Hanboonkunupakarn, Borimas |4 aut | |
| 700 | 1 | |a Poovorawan, Kittiyod |4 aut | |
| 700 | 1 | |a Imwong, Mallika |4 aut | |
| 700 | 1 | |a Taylor, Walter RJ |4 aut | |
| 700 | 1 | |a Chotivanich, Vasin |4 aut | |
| 700 | 1 | |a Chotivanich, Kesinee |4 aut | |
| 700 | 1 | |a Pukrittayakamee, Sasithon |4 aut | |
| 700 | 1 | |a Dondorp, Arjen M |4 aut | |
| 700 | 1 | |a Day, Nicholas PJ |4 aut | |
| 700 | 1 | |a Teixeira, Mauro M |4 aut | |
| 700 | 1 | |a Piyaphanee, Watcharapong |4 aut | |
| 700 | 1 | |a Phumratanaprapin, Weerapong |4 aut | |
| 700 | 1 | |a White, Nicholas J |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2024) vom: 22. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:01 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12879-023-08835-3 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2675703/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 01 | ||